BICKERSTAFF’S ENCEPHALITIS, GUILLAIN-BARRÉ SYNDROME AND IDIOPATHIC INTRACRANIAL HYPERTENSION

Are they related conditions?

Alfredo Damasceno¹, Marcondes C. França Jr¹, Daniel S. Pimenta², Leonardo de Deus-Silva¹, Anamarli Nucci¹, Benito P. Damasceno¹

Miller Fisher syndrome (MFS), considered a clinical variant of Guillain-Barré syndrome (GBS), is characterized by ophthalmoplegia, ataxia and areflexia¹. Antecedent of respiratory and/or gastrointestinal symptoms is frequent (up to 70%), with an average symptom-free interval of 10 days and the immune-mediated process is often associated with acute phase anti-GQ1b IgG antibodies in up to 95% of all cases². A closely related condition is Bickerstaff’s brainstem encephalitis (BBE), which presents additionally alteration of consciousness or long tract signs, but is less frequently associated with anti-GQ1b antibodies³. Their relation and nosological position have been subject of extensive discussion in the literature. Idiopathic intracranial hypertension (IIH) comprises signs of increased intracranial pressure occurring in the absence of obvious cerebral pathology⁴. Some studies have reported cases of intracranial hypertension associated with GBS, very few with MFS, but none with BBE.

We describe a distinct patient presenting initially with typical IIH findings but developing later signs of BBE, MFS and GBS. We also review evidence toward the possible link among MFS, BBE and GBS.

CASE

An obese 15 year-old female presented with a 5-days history of frontal headache, nausea, vomiting and diplopia. Two weeks earlier she had had flu-like symptoms and diarrhea. Examination disclosed normal consciousness, right sixth nerve palsy and bilateral papilledema (Fig 1) with normal visual acuity. Cerebral CT and MRI were normal. Lumbar puncture performed in the first hospitalization day revealed an opening pressure of 100 cm H2O, and 25 mL of cerebrospinal fluid (CSF) were withdrawn. CSF protein and cell count were 15 mg/dL and two cells per mm³, respectively (Table). Despite a transient relief, the symptoms relapsed and acetazolamide-corticosteroid combination was begun for the hypothesis of IIH. Two days later she develope-

Fig 1. Papilledema at presentation: right (A) and left (B) eye.
oped incomplete left third nerve palsy with affected visual acuity and visual field (Fig 2A). On the next day, drowsiness was observed. The symptoms worsened and on the sixth day she had a Glasgow Coma Scale (GCS) score of 11, areflexia, muscle weakness (grade 4 on the Medical Research Council scale), urinary retention and mild cerebellar ataxia. Normal laboratorial investigation excluded metabolic encephalopathy. New CSF analysis (at the 10th hospitalization day) showed increased protein with minimal pleocytosis. Serology for acute viral and bacterial infection was negative. Anti-GQ1b antibodies were not detected. Electrophysiology disclosed reduction in the amplitude of muscle action potential in facial nerves, right median and right ulnar nerves, besides slowed motor nerve conduction velocity in right ulnar nerve and diffusely absent F-responses and H-reflex. She was diagnosed with BBE and treated with intravenous gammaglobulin (0.4g/Kg/ day for 5 days). One week later she had a GCS of 15 and recovered almost completely from her ataxia, muscle weakness and urinary retention. One month later she had only a mild right sixth nerve palsy and areflexia with improved visual acuity and campimetry (Fig 2B). Five months later the Achilles reflex was present, though decreased.

A written informed consent to publish the case report was given by the patient and her legal responsible.

**DISCUSSION**

The initial clinical picture of this patient fulfilled the modified Dandy criteria for IHH. This syndrome, first described more than 100 years ago, is particularly frequent in overweight adolescent girls and is associated with different conditions such as medications, polycystic ovary syndrome and menstrual dysfunction. The pathophysiology of increased CSF pressure has not yet been completely elucidated and different mechanisms have been proposed, such as increased cerebral volume, CSF production rate and cerebral venous pressure, but impaired CSF outflow into the venous system does play an important role. The course is usually benign, though sometimes it can be complicated with visual loss.

Our patient, however, showed an atypical evolution. Within 1-week period she developed weakness, drowsiness and ophthalmoplegia, features of GBS, BBE and MFS, respectively. In GBS, co-occurrence of intracranial hypertension has been documented, with papilledema found in about 4% of affected children, and less frequently in adults. Although high protein content has been related to the mechanism of pseudotumor in GBS, it does not always play a major role, since intracranial hypertension has also been observed in patients with only mildly or moderately elevated CSF protein content, as in our case. Other mechanisms such as an immune-mediated impairment of CSF outflow into the venous system may also be related. In MFS, few cases showing signs of elevated intracranial pressure have been documented in the literature, but, to our knowledge, it has never been described with BBE. This association may be under recognized since ophthalmoscopy and CSF pressure are not routinely assessed in MFS, BBE or GBS.

<table>
<thead>
<tr>
<th>CSF parameters</th>
<th>D1</th>
<th>D4</th>
<th>D10</th>
<th>D25</th>
<th>D90</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opening pressure (cm H2O)</td>
<td>100</td>
<td>95</td>
<td>37</td>
<td>15</td>
<td>ND</td>
</tr>
<tr>
<td>Total protein (mg/L)</td>
<td>15</td>
<td>ND</td>
<td>70</td>
<td>88</td>
<td>39</td>
</tr>
<tr>
<td>Glucose (mg/L)</td>
<td>63</td>
<td>ND</td>
<td>99</td>
<td>70</td>
<td>54</td>
</tr>
<tr>
<td>Cell count (cells/mm³)</td>
<td>2</td>
<td>ND</td>
<td>5</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>

ND, not done; D1, D4, D10, D25, and D90, days of hospitalization; numbers 1, 4, 10, 25, and 90, respectively.
The classic triad of ophthalmoplegia, ataxia and areflexia was first described in 1956 by Fisher, who regarded it as an unusual variant of GBS resulting from peripheral nerve injury. Interestingly, one of his patients had drowsiness. One year later, Bickerstaff continued his previous work and reported eight patients with acute ophthalmoplegia, ataxia and altered consciousness, considering this syndrome as a form of encephalitis. Four of his patients had areflexia. Due to the similarities of these syndromes, much begun to be debated in literature, from being or not variants of the same spectrum to their nosological position as either peripheral or central. An important contribution was the finding of an antibody that reacts with peripheral nerve ganglioside GQ1b in a great number of patients with MFS and some with BBE. Further observations related this antibody to the presence of ophthalmoplegia and ataxia. Greater amounts of ganglioside GQ1b have been found in cranial nerves III, IV and VI and these nerves were enhanced by gadolinium on MRI in patients with MFS. A selective staining of the cerebellar molecular layer by serum IgG anti-GQ1b has also been observed. Although the presence of this antibody could be a secondary phenomenon due to destruction of neurons, some evidence points to a pathogenetic role, with blocking effects on the neuromuscular transmission. The appearance of this antibody has been related to cross-reactivity with lipopolysaccharide in the bacterial coat of Campylobacter jejuni, especially those with a particular polymorphism (Asn51) of cst-II gene. The anti-GQ1b antibodies were not detected in our patient, pointing more to the BBE side of the possible “MFS-BBE spectrum”.

Another valuable contribution came from studies with brain imaging describing abnormalities in some cases of BBE. In about 30% of the patients, high-signal lesions on T2-weighted scans were found in the brainstem, thalamus, cerebellum and cerebrum. A study with PET scan also found involvement of brainstem and cerebellum. Similar findings have also been reported in patients diagnosed with MFS, even in the absence of drowsiness or long tract signs, pointing to a central involvement in both MFS and BBE. Also supporting the spectrum hypothesis has been the evidence of concomitant central and peripheral abnormalities described by Ogawara et al. More, symptoms of central involvement in MFS, such as a mild somnolence, may not always be recognized.

The relation of these syndromes to GBS has been proposed since the first description of Bickerstaff and Fisher, and supported by several overlapping cases describing the presence of muscle weakness and albuminocytologic dissociation in addition to the classic triad of Fisher and/or altered consciousness or extensor plantar responses. The prognosis, however, is usually benign, especially in the “classical” MFS, and while in GBS treatment with plasmapheresis or immunoglobulin is widely recommended, in MFS they are not always necessary. In BBE or MFS/BBE overlapping cases, this treatment has been associated with beneficial effects, but randomized controlled trials are needed to establish the value of immunotherapies or other treatments. Our patient received a 5-days course of immunoglobulin, but her improvement may be attributed either to the natural history of the disease or to the treatment.

Finally, this case shows a remarkable presentation of BBE with intracranial hypertension, a condition previously associated with GBS or MFS alone. It also contributes to the understanding of the “MFS-BBE spectrum” or acute inflammatory encephaloradiculoneuritis, which may be considered as a variant of GBS, presenting both peripheral and central involvement.

REFERENCES